Previous close | 935.25 |
Open | 938.00 |
Bid | 947.91 x 200 |
Ask | 949.17 x 5000 |
Day's range | 930.00 - 957.00 |
52-week range | 910.00 - 1,400.00 |
Volume | |
Avg. volume | 2,548 |
Market cap | 1.195T |
Beta (5Y monthly) | 0.51 |
PE ratio (TTM) | 9.82 |
EPS (TTM) | 96.87 |
Earnings date | 31 Jul 2024 - 05 Aug 2024 |
Forward dividend & yield | 45.63 (4.80%) |
Ex-dividend date | 19 Apr 2024 |
1y target est | N/A |
Shares in the drug chain and health insurer lost 19% after missing earnings and slashing guidance. The culprit: Costs for its Medicare Advantage plans.
Aetna has agreed to settle a lawsuit that accused the health insurer of discriminating against LGBTQ+ customers in need of fertility treatment. Under the deal announced Friday, the insurer will make coverage of artificial insemination standard for all customers nationally and work to ensure that patients have equal access to more expensive in-vitro fertilization procedures, according to the National Women’s Law Center, which represented plaintiffs in the case. Aetna, the health insurance arm of CVS Health Corp., covers nearly 19 million people with commercial coverage, including employer-sponsored health insurance.
Aetna will pay $2 million and update its coverage policies to settle a lawsuit claiming the health insurer required LGBTQ beneficiaries to pay more out of pocket for fertility treatments than heterosexual people, according to a Friday court filing. Lawyers for four people who in 2021 sued Aetna, a subsidiary of CVS Health Corp, asked a Manhattan federal court to approve the settlement, in which the company agreed to establish a new standard health benefit plan that covers artificial insemination regardless of sexual orientation. Previously, Aetna required heterosexual couples simply to represent that they had tried for six or 12 months to get pregnant before covering fertility treatments.